To include your compound in the COVID-19 Resource Center, submit it here.

FDA’s framework seeks to clear the path for drug companies to create apps for patients

Under a framework FDA released Monday, biopharma companies could disseminate a wide range of apps and other software without submitting it for premarket review.

The proposed prescription drug use related software (PDURS) framework would treat

Read the full 353 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers